(2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid | CAS:136465-98-0

We serve (2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid CAS:136465-98-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid

Chemical Name:(2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid
CAS.NO:136465-98-0
Synonyms:(2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid
N-(2-Quinolinylcarbonyl)-L-aspargine
N-(quinolin-2-ylcarbonyl)-L-asparagine
(S)-4-AMINO-4-OXO-2-(QUINOLINE-2-CARBOXAMIDO)BUTANOICACID
N2-(2-quinolinylcarbonyl)-L-asparagine
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 723.3±60.0 °C at 760 mmHg
Molecular Formula C14H13N3O4
Molecular Weight 287.271
Flash Point 391.3±32.9 °C
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Saquinavir(CAS:127779-20-8).



Contact us for information like (2S)-2-[(quinoline-2-carbonyl)-amino]-succinamic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N2-(2-quinolinylcarbonyl)-L-asparagine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-4-AMINO-4-OXO-2-(QUINOLINE-2-CARBOXAMIDO)BUTANOICACID Use and application,N2-(2-quinolinylcarbonyl)-L-asparagine technical grade,usp/ep/jp grade.


Related News: Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.4-Methylcyclohexylamine Hydrochloride manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.3-Bromo-3-iodo-1,1-biphenyl supplier The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”Vincamine vendor The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.